• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AHI 3.59% $1.30

ADVANCED HUMAN IMAGING LTD - Corporate Spotlight

Advanced Human Imaging has developed and patented a proprietary dimensioning technology... Advanced Human Imaging has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimensions using only a smartphone privately and accurately.More

Recently Updated

Corporate Spotlight

Advanced Human Imaging has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimensions using only a smartphone privately and accurately.
View the full Corporate Spotlight arrow Created with Sketch.

AHI SIGN DEAL WITH E.U. HEALTH PROVIDER

AHI SIGNS TERM SHEET WITH CUBERT

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Health Care

ASX:AHI
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald
CEO, Vlado Bosanac
Source: Advanced Human Imaging

  • Advanced Human Imaging (AHI) signs a binding term sheet with Toronto-based digital health provider Cubert Inc
  • Under the term sheet, AHI will integrate its technology into Cubert's FitTrack platform to release a new offering called FitScan
  • FitScan will enable users to privately check, track and assess their wellness as well as predict potential health risks from their phone
  • Launch is expected in Q1 2022 and the platform will be available across both iOS and Android devices

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.


Cubert's preventative health screening app FitTrack has a global audience of over one million active users.


FitTrack is supported and used by celebrity ambassadors and collaborators such as reality TV star Khloe Kardashian.


Under the term sheet, AHI will integrate its technology into the FitTrack platform to release a new offering called FitScan.


FitScan will be available in Q1 2022 across both iOS and Android devices and will allow users to privately check, track and assess wellness as well as predict potential health risks all from their phone.


FitScan will include FaceScan which measures key health metrics such as heart rate, blood pressure, respiratory rate and risks associated with cardiovascular disease, heart attacks and strokes.


BodyScan will include innovative technology and image processing to determine body circumference, body composition and obesity and diabetes risks.


"Adding physical dimensions along with body composition to the FitTrack application will drive deeper engagement with existing users, whilst opening up the use case to a broader audience that have not yet purchased a FitTrack device," AHI Co-Founder and CEO Vlado Bosanac said.


AHI has the right to terminate the agreement if FitTrack fails to reach a minimum user number of 200,000 in the first year of commercial launch.


"We want to give our users the tools to take control of their personal health journeys, with AHI as our software partner, we are enabling FitTrack users to use their personal devices to perform simple but cutting-edge health assessments in the safety and comfort of their home," FitTrack Founder and CEO Jeff Lee said.


"The innovative software will launch in early 2022, cementing FitTrack's position at the leading-edge of the consumer health-tech industry and one step closer to providing a complete holistic health solution for consumers."


Read the Full Article on The Market Herald here

AHI SIGN DEAL WITH E.U. HEALTH PROVIDER

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI) sign deal with E.U. health services provider

Health Care

ASX:AHI
MyFiziq (ASX:MYQ) races to partner with U.S. fitness brand

  • Advanced Human Imaging (AHI) has signed a binding term sheet with European and Dutch mental health services provider Inter-Psy
  • The Netherlands-based business has developed Health i Check, a preventive screening platform which is due to go live on both iOS and Android devices
  • AHI wants to integrate its medical imaging platform with Health i Check and market it towards people improving their life via food and exercise changes
  • Under the term sheet, AHI and Inter-Psy are aiming to launch the combined product in October, with the hope of reaching 200,000 users within 12 months

Advanced Human Imaging (AHI) has signed a binding term sheet with European and Dutch mental health services provider Inter-Psy.


The Netherlands-based business has developed Health i Check, which works as a preventive screening platform.


The Health i Check app is due to go live on both iOS and Android devices in the Netherlands in June this year.


AHI wants to integrate its medical imaging platform with Inter-Psy's product and market it towards people improving their life via food and exercise changes.


The integrated product is also being designed to work alongside government programs aimed at improving the health of overweight people.


Under the term sheet, AHI and Inter-Psy are aiming to launch their combined Health i Check product in October.


The Netherlands business has an initial target of reaching 200,000 users within 12 months, however, there's no financial penalty if it fails to hit this mark.


AHI also specifies in today's binding term sheet announcement it "does not expect any immediate material financial return" from the agreement.


Instead, AHI CEO Vlado Bosanac explained his company was keen to work with a business focussed on improving people's lives.


"Providing at risk individuals with early warning signs and setting them on a healthier lifestyle course, not only benefits the individual, it has also been proven to lead to a longer, healthier lifespan," he explained.


"This initiative is based on identifying the early warning signs, which our technology can assist in identification of the markers of such lifestyle diseases," he said.


"This is the first of our partners to leverage government funded programs when providing our technology to end users free of charge," the CEO added.


Read the Full Article on The Market Herald here

AHI SHARES JUMP ON JANA CARE DEAL

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI) shares jump on Jana Care deal

Health Care

ASX:AHI   
Advanced Human Imaging (ASX:AHI) - Chairman & CEO Vlado Bosanac - The Market Herald
Chairman & CEO Vlado Bosanac

  • Medical imaging company Advanced Human Imaging (AHI) has signed a deal with U.S. pathology company Jana Care to integrate technologies

  • Jana has developed and patented an on-device blood screening tool called Aina
  • The blood test delivers rapid and accurate readouts that are valuable for health management apps like AHI's CompleteScan
  • Under the agreement, the parties will combine Jana's Habits app into the CompleteScan platform, with the first demonstrable product expected in the third quarter
  • Additionally, AHI will have an option to purchase a strategic interest in Jana
  • On the market this morning, AHI is up 11.1 per cent and is trading at $1.75 per share


    Advanced Human Imaging (AHI) has signed a deal with U.S. pathology company Jana Care to integrate technologies.

Jana has developed and patented an on-device blood screening tool called Aina.


Aina is the size of a matchbox and uses a very small strip of paper treated with analytes that react to a drop of blood from the user. The strip is inserted into the Aina device which then provides results and transfers the data to the user's smartphone.


The data brings lab-quality blood tests to individuals, doctors, healthcare workers and their patients and avoids the need for patients to go to a medical facility to provide blood and then wait for the results over days.


The blood test delivers rapid and accurate readouts that are valuable for health management apps like AHI's CompleteScan.

Under the agreement, the parties will combine Jana's Habits app into the CompleteScan platform, with the first demonstrable product being made available in the third quarter.


AHI will include Jana's Aina device as an add-on to its suite of healthcare information technologies that run on a user's smartphone.


"The commercial distribution arrangement we have undertaken with Jana is an extremely important addition to the remote care and health assessment platform we are delivering to our partners and the vast communities they service around the world," AHI CEO Vlado Bosanac said.


"I am excited with this latest partnership and how it brings AHI a full circle approach to individualized care and identification. My intention is to support all on-device capabilities by the close of 2021, with FaceScan, BodyScan, DermaScan, MSKScan and VeniScan," he added.


Jana Care CEO Rajen Dalal says the parties' technologies are the perfect fit.


"Jana Care’s quantitative digital fingerstick tests for heart, kidney, and diabetes, combined with AHI’s MultiScan suite of optical imaging applications using the smartphone, complete the circle to provide a 360- degree view of an individual’s health and wellness," he said.


"COVID put to rest any lingering doubts there may have been regarding the potential value of remote monitoring with smartphone-based telemedicine and telediagnostics. We are only at the beginning of this digital health revolution and will see the impact of these technologies grow in the near future as they help reduce the progression of chronic disease and reduce healthcare costs," he added.

Additionally, AHI will have an option to purchase a strategic interest in Jana.


To read the full article on The Market Herald click here.

DERMASCAN GIVEN ALL-CLEAR IN EURO MARKET

arrow-down-2 Created with Sketch.

Advanced Human Imaging’s (ASX:AHI) DermaScan AI given all-clear for European markets

Health Care

MyFiziq (ASX:MYQ) - CEO & Co Founder, Vlado Bosanac - The Market Herald
CEO & Co Founder, Vlado Bosanac
Source: Balance The Grind

  • Advanced Human Imaging (AHI) has been granted medical device approval for DermaScan AI across all 27 countries in the European Union
  • The ASX-lister received European Conformity approval for its DermaScan AI engine — which has been developed and patented by AHI's partner Triage
  • The European Conformity approval means Derma AI, which hosts the ability to identify 588 skin conditions in 133 categories including cancers, can now be used in over 200 countries, according to AHI
  • Further to this, DermaScan is also set to be embedded into AHI's CompleteScan health management app later this year

Advanced Human Imaging (AHI) has been granted medical device approval for DermaScan AI across all 27 countries in the European Union.


The DermaScan AI engine — which has been developed and patented by AHI's partner Triage — can identify 588 skin conditions in 133 categories and is reported to identify all categories of skin cancers.


According to AHI, the European Conformity approval means Derma AI can now be used in over 200 countries, allowing the technology to detect and identify skin conditions across all skin types.


Further to this, DermaScan is also set to be embedded into AHI's CompleteScan health management app later this year.


Broadly, the ASX-lister said receiving CE Mark approval marks a substantive milestone for the company and its partnership with Triage, with FDA approval for the U.S. expected in the second half of this year.


In addition, Triage has signed a distribution agreement with SkinHealth Canada group to supply 2000 professionals in Canada with these DermaScan AI capabilities.


Advanced Human Imaging's Chief Executive Officer Vlado Bosanac said the approval opens up the market significantly for AHI and Triage.


"On the back of Google announcing their entry into the world of AI-driven dermatology last week, I am elated with the granting of the CE medical device approval for the Derma AI," he commented.


Read the Full Article on The Market Herald

AHI SIGNS AGREEMENT WITH E-MERSION MEDIA

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI) signs agreement with e-Mersion Media

Health Care

ASX:AHI
Advanced Human Imaging (ASX:AHI) - CEO Vlado Bosanac - The Market Herald

  • Healthcare stock Advanced Human Imaging (AHI) has signed a binding terms sheet with e-Mersion Media
  • Under the agreement, e-Mersion will deliver AHI's technology via its in-publication portal
  • This will allow AHI's scans to be carried out inside e-Mersion's range of digital magazines
  • Both companies are hoping to combine their tech and launch an initial product by July, with AHI and e-Mersion to split the revenue
  • Advanced Human Imaging will also carry out cost recovery and charge US$1.99 (around A$2.57) per scan
  • Shares in AHI are trading down 5.17 per cent at $1.10 per share

Healthcare stock Advanced Human Imaging (AHI) has signed a binding terms sheet with Melbourne business e-Mersion Media.


Under the agreement, e-Mersion will deliver AHI's technology via its in-publication portal.


This will allow AHI's scanning tech to be carried out inside e-Mersion range of digital magazines.


e-Mersion is in charge of designing the relevant media assets within the publications — including a reader-specific call to action.


The company explained this could be a heart-rate check for a sport publication or a body scan for a clothing and retail magazine.


Both AHI and e-Mersion are hoping to combine their technology and launch an initial product by July, with the companies to split the revenue.


Advanced Human Imaging will also carry out cost recovery and charge US$1.99 (around A$2.57) per scan as part of the agreement.


"I was floored by the level of interaction and how the content was a combination of touch, video, and sound," AHI CEO VLado Bosanac said of the e-Mersion digital publication technology.


"I can see people interacting with this enhanced magazine technology and using their in-device camera empowered with our technology to have a health check or simply size a garment before they order right there in the magazine," he said.


"This market access is a game-changer, validated by the fact that e-Mersion has secured partnerships with Formula One World Championships, Retail inMotion, and Robb Report," he added.


Read the Full Article on The Market Herald here

AHI SIGNS AGREEMENT WITH TINJOY

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI) signs marketing agreement with Tinjoy

Health Care

ASX:AHI    
Advanced Human Imaging (ASX:AHI) - Chairman & CEO Vlado Bosanac - The Market Herald
Chairman & CEO Vlado Bosanac


  • Advanced Human Imaging (AHI) has signed a marketing agreement with Tinjoy Biotech ahead of the launch of the two companies' combined product
  • AHI's BodyScan and FaceScan technology will be integrated into Tinjoy's WinScan offering in China by July this year
  • The ASX-lister's CompleteScan technology will eventually be integrated into WinScan as well, with extensive promotion planned ahead of the launch
  • Advanced Human Imaging has announced today it'll hand US$200,000 (around A$258,000) to Tinjoy to help the planned promotion
  • This specific promotion is designed to help Tinjoy reach an initial one million monthly active users as part of its overall agreement with AHI

Advanced Human Imaging (AHI) has signed a marketing agreement with Tinjoy Biotech ahead of the launch of the companies' combined product.


The two businesses signed an agreement in February this year to integrate AHI's BodyScan and FaceScan technology into Tinjoy's WinScan offering.


At this stage, AHI and Tinjoy's integrated product is on track to launch in July, while the ASX-lister's CompleteScan technology will eventually be integrated into WinScan as well.


Ahead of that final integration, a marketing strategy has been implemented with 500 call centre team members being trained in demonstrating the functionality of the integrated WinScan offering.


Meanwhile, Advanced Human Imaging has announced today it'll hand over US$200,000 (around A$258,000) in three tranches to Tinjoy to help this planned promotion of the integrated product.


This specific promotion is also designed to help Tinjoy work towards hitting the agreed target of an initial one million monthly active users as part of its overall agreement with AHI.


Tinjoy currently services around 28 million monthly consumers both digitally and in person in China with its various health offerings.


"We will be offering the CompleteScan experience to all of our customers as a way to have them monitor their personal health and then communicate this back to our teams to deliver better more understandable care," Tinjoy Executive Director Russell Bateman said.

"We are excited to work with Advanced Human Imaging and to bring this comprehensive and innovative digital health evaluation platform to WinScan and the enormity of the China market," he added.


Advanced Human Imaging Chairman and CEO Vlado Bosanac said the integration with WinScan was progressing well.


"Our teams have been in constant communications over the last 8 weeks progressing the application integration points," the AHI CEO said.


"The production is moving well, and Russell has been a major driver on the Tinjoy side, making sure communication flows and we meet our target release date," he added.



Read the full article on The Market Herald here.

AHI BEGINS TESTING COMPLETESCAN PILOT

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI) begins testing CompleteScan pilot

Health Care

ASX:AHI
MyFiziq (ASX:MYQ) receives US$450,000 to progress Nasdaq listing

  • Advanced Human Imaging (AHI) will run a test pilot on its CompleteScan offering in partnership with Discovery Vitality
  • The business is a subsidiary of financial services and insurance provider Discovery and its Vitality shared-value insurance model attracts over 20 million members across 28 countries
  • AHI and Discovery have spent the last year testing the ASX-lister's various medical imaging products, which can be accessed from a smartphone
  • Under this latest partnership though, Discovery will spend the month of May testing the real-time data accuracy and efficiencies of CompleteScan
  • The consumer-facing pilot will take place at four Discovery facilities in South Africa, with specialists testing AHI's results against traditional health evaluations
  • Additionally, commercial discussions are continuing between AHI and Discovery about ongoing access to the application


Advanced Human Imaging (AHI) has announced a consumer pilot, which is running accuracy tests on its CompleteScan offering, has gotten underway with partner Discovery Vitality.


The business is a subsidiary of financial services and insurance provider Discovery, and its Vitality shared-value insurance model attracts over 20 million members across 28 countries.


Meanwhile, Advanced Human Imaging's tech can all be accessed and used by a person from a smartphone, while CompleteScan combines all of the various medical imaging products into one platform.


Together, AHI and Discovery Vitality have spent the last year testing the ASX-lister's various medical imaging products.

Under this latest partnership, Discovery has committed to spend the month of May testing the real-time data accuracy and efficiencies of CompleteScan.


The consumer-facing pilot will take place at four Discovery facilities located across South Africa, with wellness specialists essentially testing AHI's results against traditional health evaluations.


In addition to the pilot and testing work, AHI and Discovery are in commercial discussion for the ongoing access to the application.


"The CompleteScan integration will deliver a high-quality cost-effective data set, which will have exponential value in risk assessment and management when integrated into a solution like Vitality," AHI CEO Vlado Bosanac said.


"Better health outcomes mean better quality of life. The ethos of a platform of this nature is to do exactly that, help people live better healthier lives," he added.


"This is where the CompleteScan application is most effective, by identifying negative health indicators through actionable data for early intervention," Vlado explained.


Read the Full Article on The Market Herald here

AHI ONE STEP CLOSER TO PHYSIMAX BUYOUT

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI) one step closer to Physimax buyout

Health Care

ASX:AHI
Advanced Human Imaging (ASX:AHI) - CEO Vlado Bosanac - The Market Herald
CEO Vlado Bosanac
Source: The Big Smoke

  • Medical imaging company Advanced Human Imaging (AHI) is one step closer to purchasing Israeli-based musculoskeletal assessment company Physimax Technologies
  • Under a binding heads of agreement, AHI will now undergo its due diligence processes, which are expected to be completed next month
  • If all conditions are met, AHI will pay an all-share consideration worth US$6 million (around A$7.74 million) for Physimax as well as an additional US$2 million (about A$2.58 million) as part of an earn-in agreement
  • Physimax has developed a video-based solution that tracks and improves musculoskeletal wellness and performance by analysing the condition using a mobile device
  • Notably, Physimax has been chosen by top healthcare providers, elite sporting organisations, such as NFL and NBL, U.S. military units and colleges



Advanced Human Imaging (AHI) is one step closer to purchasing Israeli-based musculoskeletal assessment company Physimax Technologies.


Last week, the parties announced the proposed acquisition with a letter of intent.


Today, a binding heads of agreement has been executed under which AHI will conduct due diligence on Physimax, which it expects to complete around May 21, 2021.


If all conditions are met, AHI will pay an all-share consideration worth US$6 million (around A$7.74 million) for Physimax, as well as an additional US$2 million (about A$2.58 million) as part of an earn-in agreement.


Physimax has developed a video-based solution that tracks and improves musculoskeletal wellness and performance by analysing the condition using a mobile device.


Its technology automatically measures and scores mobility, stability, strength, and movement control according to evidence-based body movement patterns.


Additionally, the technology will then provide a personalised workout program for each individual.


The machine learning technology is commercially available for healthy individuals and patients undergoing rehabilitation.


Notably, Physimax has been chosen by top healthcare providers, elite sporting organisations, such as NFL and NBL, U.S. military units and colleges.


"The musculoskeletal assessment space is seeing accelerated interest, with a number of insurance and care-based platforms having adopted Musculoskeletal assessment, being Dario Health, Hinge Health and Carrum Health, all now adding offerings within their customer care initiatives," AHI CEO and Chairman Vlado Bosanac said.


"With the AHI on device 2D/3D capturing capabilities of our patented system, we anticipate that, should the acquisition proceed, we will further enhance the Physimax system in readiness for a global approach to these new capabilities," he added.


Musculoskeletal issues include more than 150 conditions that affect the locomotor system of individuals. These include short-term conditions — such as fractures, sprains and strains — to lifelong conditions associated with ongoing limitations and disability.


Importantly, musculoskeletal conditions are the highest contributor to the global need for rehabilitation.

"AHI will continue to identify opportunities of this kind that are complementary to the AHI offering, with a view to either a partnership, or when advantageous, acquisition," Vlado concluded.


Read the Full Article on The Market Herald here

AHI LAUNCHES NEW PARTNERSHIP

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI) launches partnership with The Original Fit Factory

Health Care

ASX:AHI   
Advanced Human Imaging (ASX:AHI): a unique opportunity in the massive telehealth market


  • Advanced Human Imaging's (AHI) BodyScan technology has been integrated into the TRUCONNECT app and launched on Apple Store
  • The app is being run by The Original Fit Factory (TOFF) and boasts an audience of over 150 million people across 71 different countries
  • TRUCONNECT will soon be available to Android users as well, with plans to launch on the Google store on April 26
  • To promote AHI's technology within TOFF's app, the companies will offer a 36-hour worldwide free body scan beginning on May 8
  • The event will be accompanied by a special offer of a 30-day unlimited body scan subscription for £4.99 a month (around A$9)
  • As part of the two-year agreement between AHI and TOFF, the partner will target one million active users within the first 12 months
  • Shares in Advanced Human Imaging are trading up 2.21 per cent at $1.85 per share




Advanced Human Imaging's (AHI) BodyScan technology has been integrated into the TRUCONNECT app and launched on Apple Store.


The app is being run by The Original Fit Factory (TOFF) and boasts an audience of over 150 million people across 71 different countries.


TRUCONNECT also partners with groups like Huawei, influencer Amanda Cerny, MMA star Georges Saint Pierre and Bollywood actress Jacqueline Fernandez.


Along with the soft launch on Apple, TOFF's app will soon be available to Android users as well, with plans to launch on the Google store on April 26.


To promote AHI's technology being integrated within TOFF's app, the companies have announced they'll offer a 36-hour worldwide free body scan beginning on Saturday, May 8.


The free event will also be accompanied by a special offer, to be sent out via notifications, offering a 30-day unlimited body scan subscription for £4.99 a month (around A$9).


Commenting on the milestone, Advanced Human Imaging CEO Vlado Bosanac said it was a "game-changer" for the fitness industry.


"The addition of our BodyScan to the TRUCONNECT app is going to be a game-changing experience to the standard exercise regimes currently being offered in applications of this kind," he explained.


"TRUCONNECT users will now be able to understand and map the changes they experience through the digital tracking capabilities of the AHI technology as they work out with their trainers and follow the plans set out for them," he added.


"The feedback loops our technology supplies TRUCONNECT, and its users will provide better engagement and understanding of the user’s results, empowering TRUCONNECT and their trainers with the data they need to support their users in achieving better outcomes," Vlado said.


As part of the two-year agreement between AHI and TOFF, the partner will target one million active users within the first 12 months. That said, this target isn't binding.


To read the full article on The Market Herald click here. 

AHI FINALISES ONE DEAL & SIGNS ANOTHER

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI) finalises one deal & signs another

Health Care

ASX:AHI    
Advanced Human Imaging (ASX:AHI) - CEO Vlado Bosanac - The Market Herald
CEO Vlado Bosanac

  • Advanced Human Imaging (AHI) has completed due diligence and entered an agreement with Triage Technologies, while also announcing another deal
  • The healthcare business revealed on Monday it is planning to acquire musculoskeletal assessment (MSK) company Physimax Technologies
  • Under this latest deal, AHI would pay US$6 million (around A$7.75 million) in consideration for Physimax, with a letter of intent already signed
  • AHI is interested in acquiring the company's technology, a video-based objective solution that tracks and improves MSK wellness and performance
  • Meanwhile, under its deal with Triage, Advanced Human Imaging has also gained access to the company's dermatological technology which can identify hundreds of different skin conditions

Advanced Human Imaging (AHI) has completed due diligence and entered an agreement with Triage Technologies, while also announcing another key deal.


Latest agreement

The medical imaging company came out of a voluntary suspension to announce today it's planning to acquire musculoskeletal assessment (MSK) company Physimax Technologies.


The Israeli-based business has developed a video-based objective solution that tracks and improves MSK wellness and performance via footage capture using a mobile phone.


AHI has signed a letter of intent ahead of the proposed acquisition, agreeing to pay US$6 million (around A$7.75 million) in consideration for Physimax as well as an additional US$2 million (about A$2.58 million) as part of an earn-in agreement.


"Physimax would be a welcome addition to the AHI MultiScan platform. The Physimax team has spent seven years developing, validating and commercializing the technology and has seen broad acceptance of the application worldwide with over 250,000 scans performed to date," AHI CEO Vlado Bosanac said.


"The technology is being used in multiple facets of care and Musculoskeletal enhancement throughout the US, Europe and Asia. The use of the platform is well documented and used by the NBA, clinicians, U.S. military and universities around the world," he added.


Triage deal

Now, with a binding technology licence and subscription agreement under its wing, AHI is one step closer to finalising its deal with Triage Technologies.


AHI plans to integrate Triage's advanced dermatological artificial intelligence system, which can accurately identify up to 588 skin conditions, into its own CompleteScan product.


The integration is expected to be completed sometime during the third quarter of 2021, with the ASX-lister agreeing to invest US$6 million (roughly A$7.75 million) in Triage in return.


The payment will be made in both cash and shares, with AHI already handing over US$600,000 (approximately A$775,000).


Advanced Human Imaging shares are trading down 5.61 per cent at $1.94 per share at the close of trading on Monday.



Read the full article on The Market Herald here.

AHI: A UNIQUE OPPORTUNITY IN TELEHEALTH

arrow-down-2 Created with Sketch.

Advanced Human Imaging (ASX:AHI): a unique opportunity in the massive Telehealth market


ASX:AHI    
Advanced Human Imaging (ASX:AHI): a unique opportunity in the massive telehealth market


  • The global healthcare market is in the midst of a significant transformation as major tech innovations drive the demand for digital health
  • The likes of Amazon, Apple, and AstraZeneca have noticed the potential of the Telehealth market
  • Grand View predicts the U.S. Telehealth market alone will be worth just shy of US$3 billion (around A$3.9 billion) by the end of 2022
  • Advanced Human Imaging (AHI) has developed its unique mobile phone-based body imaging technology and offers BodyScan, FaceScan, and DermaScan imaging capabilities, but has plans to create an all-encompassing medical imaging solution
  • Advanced Human Imaging presents a unique opportunity for investors to take part in the upcoming healthcare revolution

The global healthcare market is in the midst of a significant transformation as major tech innovations drive the demand for digital health.


From doctors' appointments to pill prescriptions to at-home diagnostic kits, consumers are increasingly able to access high-quality healthcare from the comfort of their own home.


And this trend has only been magnified by the COVID-19 pandemic. With government stay-at-home mandates and calls to self-isolate shaping the past year, the need for non-contact healthcare has grown.


After noticing the potential of this lucrative market, ASX-listed Advanced Human Imaging (AHI) has been tackling the digital health sector with its unique mobile phone-based personalised diagnostic imaging technology.


With its proven tech platform, strong management team and upcoming NASDAQ listing, the company has laid the foundations to become a textbook tech success story on the Australian market.


Yet, AHI is not alone in its journey to transform digital health; some of the biggest players in the world of tech have noticed the potential of the Telehealth market and began to develop their own technology to grab their share.


The Telehealth explosion


Telehealth has become a commodity. While this type of healthcare is crucial when considering lockdowns and self-isolation requirements, the fact of the matter is that Telehealth brings the healthcare market up to speed with how consumers interact with the world around them.


It's for this reason Amazon launched its Amazon Care Telehealth service in 2019, followed by Amazon Pharmacy in late-2020.


These services offer 24/7 health services at the click of a button; consumers can book online doctors' appointments at any time and complete the entire consultation via text, images and video calls.


This means no more waiting rooms and travel times. Further, prescriptions can be delivered to your door if required, and if in-person consultation is crucial, a doctor can be sent to your home.


And it's not just Amazon. Apple CEO Tim Cook flagged in January 2019 that the tech giant's future lies in the healthcare market.


"If you zoomed out into the future, and you look back, and you ask the question, 'What was Apple's greatest contribution to mankind?' it will be about health," Tim told Mad Money's Jim Cramer.


This statement has become something of a mantra for the Apple boss, with Tim Cook repeating the phrase — almost word for word — several times since then.


He says he believes big tech will play a role in driving down healthcare costs through digital consultations and simple, quick disease detection and prevention. Healthcare will be Apple's greatest legacy.


Even biotech giant AstraZeneca, which is playing a critical role in COVID-19 vaccine development, is turning to the digital health market. The company has flagged in 2021 that it believes digital tools will become the new standard of healthcare alongside drug prescriptions.


AstraZeneca is moving forward with plans to eventually prescribe two products for patients with chronic conditions: a drug to treat the disease and a digital kit to tell clinicians whether the drug is taken as prescribed and provide other crucial insights typically only available if a patient is monitored in a hospital.


Market researcher Grand View predicts the U.S. Telehealth market alone will be worth just shy of US$3 billion (around A$3.9 billion) by the end of 2022.


Further, Issuu expects the virtual diagnostic segment of the Telehealth market to hit US$1.5 billion (around A$2 billion) by 2027.


And this is the market Advanced Human Imaging is targeting as it joins the ranks of tech businesses committing to the future of digital health.


All-encompassing medical imaging


Advanced Human Imaging offers unique and accurate body measurements at the click of a button.


Through nothing more than a mobile phone, users can measure the human form across 12,000 data points to analyse key vital markers with an accuracy usually only available in a clinic.


As it stands, AHI offers three types of human body scanning capabilities. BodyScan images body circumference and composition to read biometric markers associated with conditions like cardiovascular disease, obesity, and Type 2 diabetes.


FaceScan is able to detect subtle skin colour changes through blood flow in the face which can indicate blood pressure, cardiac load, heart rate, respiratory rate, risk of stroke and more.


Finally, DermaScan can detect skin diseases and markers associated with over 580 skin conditions in 133 different categories. DermaScan has over 160,000 users and has been used over 500,000 times, with 12 per cent of its userbase being clinicians.


Yet, while there are a handful of competitors tackling specific aspects of handheld imaging, the spoils will go to the company that combines it all.


This is why AHI has a clear vision and strategy to create an accessible all-encompassing medical solution to make the lives of doctors and patients easier.


The company is working towards expanding its digital imaging offering to include multiple clinic-based diagnostics to complete is offering.


AHI has clear plans for its full handheld imaging suite, but there is one other clear advantage that sets the business apart from competitors: the mobile phone.



The AHI difference

Other tech specialists across the globe have emerged offering revolutionary digital health equipment.


Take, for example, a recent partnership between New York-based healthcare specialist TytoCare and Florida's Tampa General Hospital to create an at-home medical kit for virtual medical exams.


While this tech is certainly ground-breaking, it requires consumers to purchase a full at-home Telehealth kit, which patients and clinicians will need to spend time learning how to use properly. The focus of this kit will be to provide medical exams of lungs, heart, throat, skin, heart rate, body temperature and more.


AHI, on the other hand, is leveraging technology that already exists to provide the same degree of expert medical analysis. The company's platform requires users to simply download an app onto the mobile phone already in their pocket.


Alternatively, Advanced Human Imaging can partner with these global tech giants and provide AHI’s services to their customer base. The business makes data and real-time personal care accessible and affordable to these tech company’s consumers by rapidly and accurately delivering information that would normally require additional equipment or human intervention.


AHI has built up a scalable body imaging platform that can be embedded into partner apps and existing technology. By doing this, the company has set itself apart from competitors for its ease-of-use and accurate imaging capabilities.


Moreover, as global tech giants power ahead with a renewed focus on the Telehealth industry, Advanced Human Imaging presents a unique opportunity for investors to take part in the upcoming healthcare revolution.


With such great strides being made in this industry so quickly, investors will need to act soon to seize their opportunity.


To read the whole article on The Market Herald click here. 

MYQ TO BECOME ADVANCED HUMAN IMAGING

arrow-down-2 Created with Sketch.

MyFiziq (ASX:MYQ) to become Advanced Human Imaging in light of its meditech transformation

ASX:MYQ    
MyFiziq (ASX:MYQ) - CEO & Executive Director, Vlado Bosanac - The Market HeraldCEO & Executive Director, Vlado Bosanac
MyFiziq (MYQ) has created a disruptive tech platform to revolutionise the medical imaging market, and the business is now changing its name to reflect its global strategy

After laying the foundations for an upcoming listing on the NASDAQ, MyFiziq is now rebranding to Advanced Human Imaging (AHI)

What's more, the company has already reserved its new ticker code on both the ASX and NASDAQ exchanges

CEO Vlado Bosanac says the new name is the natural next step for the company as it transforms from a fitness app into a true competitor in the field of medical technology

Importantly, MyFiziq says it is well-funded to hit its goals ahead of a successful NASDAQ listing — meaning there is no new capital raise on the horizon

By changing its name to Advanced Human Imaging ahead of its NASDAQ listing, MyFiziq is emerging as a prime ASX example of a transformation story

Investors who join the fray now have the opportunity to witness a game-changer in the medical imaging field first-hand



MyFiziq (MYQ) has created a disruptive tech platform to revolutionise the medical imaging market, and the business is now changing its name to reflect its global strategy. 


The body scanning and medical imaging specialist has already laid the foundations for an upcoming listing on the NASDAQ. 


Now, MyFiziq is rebranding to Advanced Human Imaging (AHI). What's more, the company has already reserved its new ticker code on both the ASX and the NASDAQ exchanges as it breaks the mould in the lucrative medical imaging sector. 


Co-founder and CEO Vlado Bosanac said the new name is the natural next step for the company as it transforms from a primarily fitness-focussed app into a true competitor in the field of medical technology.


"Changing our name from MyFiziq to Advanced Human Imaging is in line with the business' transformation from a body-tracking app to a company with full-fledged medical imaging capabilities and applications," Vlado said. 


"It's an important next step for the company as we work towards listing on the NASDAQ, where we will have access to the kind of support and high-quality investment that can only be offered by the world's leading tech exchange," he said. 


The name change was overwhelmingly approved by shareholders at an extraordinary general meeting (EGM) today, where the MYQ management team outlined its international strategy.


Shareholders at the EGM approved the name change by almost 57 million votes for to just 3,600 votes against. 


Strong balance sheet, shrewd management


Importantly, MyFiziq said it has enough funding to keep moving forward as it achieves its key goals ahead of a successful NASDAQ listing. 


"The company is well-funded to meet all of our key objectives as we take this next transformative step for the business," Vlado said. 

"We have a strong management team and sufficient resources to keep hitting goals across the board." 


As such, MyFiziq reaffirmed that there are no plans for an upcoming capital raise, with all the resources needed for its NASDAQ listing already available. 


Crucial imaging from the phone in your pocket


MyFiziq's technology gives users accurate body measurements from the convenience of their phone.


Using nothing more than a smartphone, users can measure the human form across 12,000 data points and analyse key vital markers with an effectiveness usually only available from a medical clinic.


The tech was initially used to track body measurements, weight-to-height ratios and total body fat with up to 97 per cent accuracy, providing crucial assistance in a user's weight loss journey. 


The tech has evolved, however, to read biometric markets associated with a range of chronic health conditions like cardiovascular disease, obesity and Type 2 diabetes. 


On top of this, the tech can detect subtle skin colour changes to capture key vital signs that signal blood pressure, cardiac load, heart rate, risk of stroke and more. 


And with global partnerships with the likes of Canadian skin disease specialist Triage Technologies, Australian biotech Biomorphik, and Chinese medicine and body-scanning company Tinjoy Biotech, the MYQ tech has even further to run.


Now, by changing its name to Advanced Human Imaging ahead of its listing on the NASDAQ, the business is emerging as a prime ASX example of a transformation story. 


Investors that supported the company early on have already been richly rewarded, with MyFiziq shares gaining some 2200 per cent since March 2020. 


But the best is yet to come for Advanced Human Imaging. Investors who join the fray now have the opportunity to witness a game-changer in the medical imaging field first-hand.


Read the full article on The Market Herald here.

MYQ GEARS UP FOR NASDAQ LISTING

arrow-down-2 Created with Sketch.

MyFiziq (ASX:MYQ) gears up for NASDAQ listing with substantiative new board appointments

ASX News

- Incoming Non Executive Director & Audit Committee Chair, Luisa Ingargiola - The Market Herald
Incoming Non Executive Director & Audit Committee Chair, Luisa Ingargiola

  • MyFiziq (MYQ) has appointed two new board members as it gears up to launch on the NASDAQ
  • Edward Greissing Jr and Luisa Ingargiola will join the health tech player ahead of its debut on the prominent U.S. exchange later this year and come equipped with extensive healthcare and capital markets experience
  • They will both assume non-executive director positions on the MyFiziq board, with Luisa set to become Chair of the ASX-lister's audit committee
  • MYQ Chairman and CEO Vlado Bosanac said he is "extremely pleased" to be bringing the new appointments onboard 
  • MYQ shares are up a healthy 3.13 per cent, trading at $1.81 per share

MyFiziq (MYQ) has appointed two new board members as it gears up to launch on the NASDAQ.


The health tech player today announced two new board members would join the MyFiziq entourage, upon acceptance by the prominent exchange and its official listing later this year.


Edward Greissing Jr and Luisa Ingargiola, who come equipped with extensive U.S. healthcare and capital markets experience, will both take up positions as Non-Executive Directors, with Luisa also set to chair the ASX-lister's audit committee. 


Edward Greissing Jr is a Strategic Advisor and Senior Fellow with the Milken Institute, a nonprofit think tank based in California. In the past, he’s worked as an Executive Director at the institute’s Center of Public Health.


Ultimately, his tenure across a suite of nonprofits and global businesses has shaped his focus on health outcomes, making him a great match for the MYQ team.


Edward has also served as President and CEO of Red Line Associates, a consulting firm with clients from the biopharmaceutical, device, food service, and financial industries. 


The health tech developer’s other executive hire, Luisa Ingargiola, brings further expertise to the table and will prepare MyFiziq for its NASDAQ debut.


With over 20 years’ experience in public company finance, compliance, capital markets oversight and mergers and acquisitions, Luisa resides across five NASDAQ boards as an Audit Committee Chair.


Previously, she guided several companies through their uplist or initial public offering (IPO) on major exchanges like the NASDAQ and New York Stock Exchange (NYSE). 


“I have always prided myself with the people I have around me and the skills they bring that challenge me as the CEO and Co-Founder of MyFiziq,” commented MYQ Chairman and CEO Vlado Bosanac.


“I am extremely pleased to have Edward and Luisa joining the board of MyFiziq. Both Edward and Luisa are highly respected in the global business communities and bring an endless amount of experience and knowledge across multiple facets of Business, Capital Markets, Health, Government policy and the core needs of the MyFiziq offerings,” he continued.


It seems MyFiziq’s move towards a NASDAQ listing is building momentum, with the tech stop rising into the green over Friday’s session. MYQ shares are up 3.13 per cent to $1.81 per share at 1:31 pm AEDT.



Read the full article on The Market Herald here.

SPAC JOINS MYQ TO TAKE ON $33B US MARKET

arrow-down-2 Created with Sketch.

Builder of $2.9B SPAC Beachbody deal joins MyFiziq (ASX:MYQ) to lead assault on $33B U.S. fitness market

Sponsored

ASX:MYQ    
MyFiziq (ASX:MYQ) - Chief Business Officer William Bradford - The Market Herald
Chief Business Officer William Bradford

  • MyFiziq (MYQ) has appointed a new, experienced leader in the U.S. online fitness space to join its executive management team
  • William Bradford helped broker the special purpose acquisitions company (SPAC) Beachbody deal, which is worth US$2.9 billion (about A$3.6 billion)
  • William's appointment to MYQ Chief Business Officer comes ahead of the health technology company's planned NASDAQ listing
  • MyFiziq is launching an assault on the U.S. health, fitness and gym market which has an estimated net worth of US$33.3 billion (roughly A$41.8 billion)
  • The company's CompleteScan technology has already revolutionised the medical imaging market in Australia with its online diagnostic capabilities
  • With the new leader onboard, all that's left for MyFiziq to do is stake its claim in the multi-billion-dollar U.S. health and fitness market
  • MYQ shares are trading at $1.76, up 0.57 per cent

Investors are always looking for the next big thing. The elusive company which is going to follow Apple, Amazon or even Appen (APX) in skyrocketing to success with their groundbreaking technology.


These companies all came from humble beginnings, but now dominate the various U.S. markets with their staggeringly large market caps, expensive share prices and outstanding returns. They also share a common pillar — each stock has a savvy management team behind it.


So what is the next great stock and who's leading it? One of the companies already dominating the Australian fitness market is MyFiziq (MYQ). The health technology business is also poised to triumph in the States after recently appointing an experienced leader from the U.S. digital media space to its leadership team.


William Bradford heads up another NASDAQ hopeful, and with the former Fox SVP and Beachbody leader onboard, MyFiziq is expertly placed to launch on the NASDAQ and dominate the US$33.3 billion (roughly A$41.8 billion) health and fitness market.

Imaging diagnostics transformed


MyFiziq has found success to date with its proprietary CompleteScan technology, which essentially works to read a user's vital signs, like blood pressure, heart rate, pulse and more from a body scan to provide a diagnosis on everything from chronic health conditions to skin diseases.


CompleteScan – The Future of Health Assessments from MyFiziq: Advanced Human Imaging on Vimeo.


MyFiziq has already partnered with a range of other healthcare and fitness companies, including Canada-based Triage Technologies, Australian biotechnology business Biomorphik and more recently Chinese health company Tinjoy Biotech.


MYQ's disruptive technology and various partnerships have helped the company achieve dazzling success to date, with shares jumping 614 per cent in value over the last 12 months. 


Over the course of the year, MYQ went from being worth 20 cents per share in mid-January to over $1.30 per share by the end of October. It's since gone on to top the $1.80 mark and is on track to hit $2 per share in the near term.


Not content with dominating the Australian market, though, MyFiziq has now set its sights on the U.S. market, or more specifically the NASDAQ. The company is gearing up to list on the well-known and competitive stock market — home to Facebook and Tesla — later this year.


The future of health

Ahead of the listing, MyFiziq has appointed a key leader to help it navigate the U.S. market and its high-powered investors, with William Bradford joining the team at MYQ as Chief Business Officer.


William brings a wealth of experience to the role, having previously worked as a key executive lead for multiple fortune 500 companies, including at media giant Fox Broadcasting, where he helped pioneer online voting for hit series' such as American Idol and The X Factor.


More recently, he worked as the Chief Digital Officer at leading fitness business Beachbody — helping transform the company’s media business from a transactional DVD sales model to a multi-platform consumer digital subscription service.


Such is the success of Beachbody on Demand that it currently reaches millions of customers worldwide and tables an average annual revenue of more than US$1 billion (around $1.26 billion).


Beachbody also recently announced a special purpose acquisitions company (SPAC) deal which will give the business a total worth of US$2.9 billion (about A$3.6 billion) and will see it list on the NASDAQ.


Commenting on the key appointment, MyFizq CEO Vlado Bosanac said William's experience in the U.S. market would be a key advantage for the company going forward.


"His knowledge and previous successes in transforming companies in the digital space is second to none. He was strategic in Beachbody transforming to a digital business model, which is now seen to be one of the most successful online fitness and nutrition platforms in the U.S.," he said.


Tackling a $33 billion market

With another experienced leader at the helm, MyFiziq has placed itself in an enviable position ahead of its NASDAQ launch. It's also primed to increase its existing stake in the lucrative health and fitness market.


A recent analysis by Ibis World revealed the estimated worth of the U.S. health, gym and fitness market alone is a staggering US$33.3 billion (roughly A$41.8 billion), with an estimated growth rate of 2.3 per cent.


Given MYQ's technology is one-of-a-kind and applicable to both healthcare companies looking for remote diagnostic capabilities and fitness business who want to offer health-tracking metrics, the stock's future looks limitless.


"Having watched the interest and exponential growth of the company throughout the last 12 months, my now full-time role will afford me the benefit of being singularly focused on the task at hand. We have engaged with some of the largest organisations in the US over the last 12 months and I am pleased with their interest and ongoing engagement," Chief Business Officer William Bradford said.


He argues the COVID-19 pandemic has changed the way many healthcare businesses operate, forcing them to adopt remote diagnostics technology and accept that the future of health is digital.


"Most organisations have had to pivot in some form due to the global pandemic and from my point of view, this has only strengthened the need for the platform Vlado and the team have built," he explained.


"Ever since I saw MyFiziq's technology demonstrated in person, I knew it had enormous potential. The technology is exciting, and I believe I can assist in facilitating relationships not just here in the US, but globally through both my personal network and previous roles," he added.


Armed with an experienced leadership team, ground-breaking technology and a clear path for success, MyFiziq is poised to further dominate the U.S. market when it launches on the NASDAQ later this year.


Read the full article on The Market Herald here.

MYQ TEAMS UP WITH TINJOY

arrow-down-2 Created with Sketch.

MyFiziq (ASX:MYQ) teams up with Tinjoy

Technology

ASX:MYQ    
MyFiziq (ASX:MYQ) - CEO & Co Founder, Vlado Bosanac - The Market Herald

CEO & Co Founder, Vlado Bosanac

  • MyFiziq (MYQ) has inked a deal allowing Tinjoy Biotech to use its CompleteScan platform within its own WinScan digital health platform 
  • The producer and supplier of traditional Chinese medicines services over 28 million monthly consumers and launched WinScan in 2020
  • MyFiziq and Tinjoy will combine their platforms by the third quarter of 2021, targeting one million monthly users within a year 
  • Under the terms of the agreement, MyFiziq will receive a 70 per cent split of revenue and has the option to invest in WinScan 

MyFiziq (MYQ) has inked a deal allowing Tinjoy Biotech to use its CompleteScan platform within its own WinScan digital health platform. 


The producer and supplier of traditional Chinese medicines services over 28 million monthly consumers and launched WinScan in 2020 to enlarge the company's presence in China. 


The platform addresses wellness, preventative health and nutrition with the primary focus on identifying individuals at risk of chronic disease. 


MyFiziq and Tinjoy will combine their platforms for multiple market segments in China and initially include three preliminary scans: BodyScan, FaceScan and COVID symptoms check. 


The partners are aiming to offer this combined solution from the third quarter of 2021, targeting one million monthly users within a year. Later, a DermaScan assessment will be integrated. 


The initial focus will be on training Tinjoy's existing 500 call centre staff in Nanning. MyFiziq will put in US$100,000 (around A$128,840) towards the training and US$100,000 towards marketing and launch. Tinjoy will provide sales bonuses to centre staff to drive uptake. 


"As we train the team both at call centre and pharmacy level, we will trial small pilots on the sales experience and delivery, allowing the teams to refine the delivery of the uniqueness and value this offering can bring," said Tinjoy Executive Director Russell Bateman.


"We want to help manage and guide people to better health outcomes and this addition to our offering, I believe will be not only attractive but of significant value to our customers."


Under the terms of the agreement, MyFiziq will receive a 70 per cent split of revenue and has the option to acquire up to 40 per cent of the WinScan Platform.


"I am also pleased Tinjoy views the agreement as a long-term partnership, with their openness to MyFiziq acquiring a substantive holding if the platform achieves monthly users of five million or more," said MyFiziq Chairperson and CEO Vlado Bosanac. 


"The agreed consideration would be well under the monthly revenue MyFiziq would see based on the pricing we have structured in consultation with Tinjoy," he added.



Read the full article on The Market Herald here.


MYQ AGREES TO LOAN BEARN A$645K

arrow-down-2 Created with Sketch.

MyFiziq (ASX:MYQ) agrees to loan Bearn A$645K

Health Care

ASX:MYQ    


  • MyFiziq (MYQ) has entered a funding agreement with Bearn, which runs an app that allows its customers to earn money while working out
  • MYQ has agreed to lend Bearn, a previous partner, US$500,000 (around A$645,000) to help expand the app's platform capacity
  • In return, Bearn has promised to deliver MyFiziq one million active monthly users within a year or the loan is repayable with increasing interest
  • The founder of Bearn has pledged his 88 per cent ownership in the company as security for the loan, as well as the app's software
  • MyFiziq's body scanning tech has already been integrated with the app, which has 56 million pre-registered users

Body scanning specialist MyFiziq (MYQ) has entered a new funding agreement with U.S. app creator Bearn.


The two companies have worked together before on Bearn's app, which essentially allows users to earn money while working out.

Under this latest funding agreement, MyFiziq has agreed to lend Bearn US$500,000 (around A$645,000).


The app founder had advised MYQ that running a campaign for the 56 million pre-registrations it's received to date "would not be possible based on the existing specifications of the Bearn platform."


As a result, MyFiziq has agreed to loan Bearn the cash to help it expand the app's platform capacity.


In return, Bearn has promised to deliver MYQ one million active monthly users within a year or the loan is repayable in 15 months with increasing interest.


Under the agreement, MYQ will also receive US$2 per scan (about A$2.58) undertaken by each user or an annual fee of US$47.88 (roughly A$61.80).


The founder of Bearn, Aaron Drew, has pledged his 88 per cent ownership in the company as security for the loan, as well as the app's software.


"Bearn is a great company, and it was roadblocked due to the U.S. COVID lockdowns and inability to roadshow and source new capital. I saw this as an opportunity to work with an already established partner and to enable Bearn to reach our joint goals," MyFiziq CEO Vlado Bosanac said.


"The launch of new improved Bearn app has been targeted for April 2021, giving Bearn ample time to make the platform improvements and engage the marketing campaign for the onboarding process," Vlado added.


MyFiziq's body scanning tech has already been integrated with the Bearn app under past agreements between the two parties.


Read the full article on The Market Herald here.

BIOMORPHIK LAUNCHES ON GOOGLE AND APPLE

arrow-down-2 Created with Sketch.



  • The new Biomorphik app, integrated with MyFiziq’s (MYQ) technology, has been released on both the Google Play and Apple app stores in Australia
  • The app allows users to scan themselves and track body composition changes, empowering them to make better decisions for their health and wellness
  • Under the terms of the commercial contract, Biomorphik is aiming to deliver 100,000 active monthly users to MyFiziq
  • Myfiziq is up 5.79 per cent, trading at $1.28 per share


The new Biomorphik app, integrated with MyFiziq’s (MYQ) technology, has been released on both the Google Play and Apple app stores in Australia.

The app allows users to scan themselves to track body composition changes, empowering the user to make better decisions regarding their health and wellness.

Under the terms of the commercial contract, Biomorphik is aiming to deliver 100,000 active monthly users to MyFiziq. If this undertaking is not met, MyFiziq has a right to terminate the agreements between the parties.

In line with the initial product release, Biomorphik will begin a comprehensive business-to-consumer marketing strategy to draw users to the new platform, with the first stage allowing people to monitor their bodies closely and pre-empt potential issues before they become prohibitive to the user’s health.

The Biomorphik app will offer both month-to-month and yearly payment options to consumers, with the app set to be released in South East Asia within the next three months.

Users can select from a monthly subscription of $22.99 per month for unlimited scans, or a yearly subscription payment option of $142.99 per year for unlimited scans. generally, a single Dexa body composition scan can cost up to $80.00.

“As mentioned prior to Christmas, the applications are now live and available for download. Nathaniel (CEO of Biomorphik) is programming a well-formulated marketing approach to the release over the first quarter of 2021,” Vlado Bosanac, Chief Executive Officer of MyFiziq, said:

“Once this commences, we will assist Nathaniel and Biomorphik with their campaign as needed. I believe this will be the first of the releases to take a more aggressive approach to the customer onboarding as it forms such an integral part of their customer journey and retention, through real data and supervision”.

See the Full Article Here. 

MYQ & BIOMORPHIK APP TO BE RELEASED 2021

arrow-down-2 Created with Sketch.


MyFiziq (ASX:MYQ) & Biomorphik app to be released in early 2021

Health Care

ASX:MYQ    
MyFiziq (ASX:MYQ) - CEO & Executive Director, Vlado Bosanac - The Market Herald

CEO & Executive Director, Vlado Bosanac
Source: MyFiziq


  • A health-centric mobile app, which fuses tech from body scanning specialist MyFiziq (MYQ) and Biomorphik, will be released next year
  • The two companies had been targeting an accelerated November release, but delays have occurred due to a rush of new app applications
  • MyFiziq now advises that the Biomorphik app has been registered for the Google Play and Apple App stores for release approval
  • Android and iOS users in Australia will get first access to the technology before the app is rolled out across South East Asia
  • MYQ has been guaranteed 100,000 active users onto the integrated platform in the first 12 months from launch



MyFiziq (MYQ) has announced the Biomorphik app, which incorporates the body scanning specialist's technology, will be released early next year.


The two companies had been targeting a November release, after initially announcing when the agreement was first signed that it would launch in 2021.


However, in an update released to the market today, MYQ stated that delays have occurred due to a rush of new app applications.

Instead, both businesses will push ahead with their original release date, with the app now registered on Google Play and Apple App stores for release approval.


The Biomorphik app works as a pre-emptive health platform, designed to manage wellness and reduce the overall health care cost for users and governments.


MyFiziq’s body tracking technology will be integrated into the app to better help monitor and manage the user's health and fitness.

Australian iOS and Android users will get first access to the Biomorphik app early next year, before it's pushed into wider South East Asian markets.


A range of app enhancements are planned for 2021, including the introduction of MyFiziq’s CompleteScan technology early next year.

MYQ has been guaranteed 100,000 active users onto the integrated platform in the first 12 months from launch, or it can walk away from the agreement.


"It has been a pleasure working with the Biomorphik team to accelerate this release as Biomorphik has experienced a surge of new business interest in Asia due to the COVID-19 pandemic," MYQ CEO Vlado Bosanac said.


"The accelerated product has been simplified to address this increased demand and will initially only include MyFiziq technology offering whilst Biomorphik concludes the updated offer with the Biomorphik wellness and health advisory capabilities," he added.


Next steps for MYQ and Biomorphik will involve commencing work on creating multi-language support for the app as well as a widespread business to consumer (B2C) marketing campaign ahead of the release.


Read the full article on The Market Herald here.

MYQ DISRUPT $45B MEDICAL IMAGING MARKET

arrow-down-2 Created with Sketch.


MyFiziq (ASX:MYQ) is poised to disrupt the $45B medical imaging market

MyFiziq (ASX:MYQ) receives US$450,000 to progress Nasdaq listing

  • MyFiziq's advanced human imaging technology is a game-changer for the future of healthcare
  • The tech scans the human form across 12,000 data points and interprets critical vital markers like blood pressure, heart rate variation, pulse, and more
  • These observations can be used for the early detection and prevention of chronic conditions like Type 2 diabetes, cardiovascular disease, and obesity
  • However, medicine is a conservative industry, and consumers prefer to stick with established and trusted brand names
  • This had led to a change in the way global healthcare giants operate with big brands scouring the market for the latest innovations, buying them out and then selling them under their own name
  • The likes of Siemens, GE Healthcare, and even Apple, have all hopped on this trend, with several healthcare acquisitions made over recent years
  • The potential for MyFiziq's tech to save lives and return healthy profits for investors is enormous
  • Whether MyFiziq will deliver shareholder growth and dividends or whether it will be consolidated by a global giant is not yet clear
  • One thing that's certain is that MyFiziq and its sophisticated intellectual property are poised for success
  • Shares in MYQ are trading for 99.5 cents each
    As companies across the globe scramble to find the next big breakthrough in the healthcare industry, the truth is that the future of healthcare is already in your pocket. 


The implications of a supercomputer you can hold in your hand go far beyond emails on the go and constant access to social media. 


Apple's CEO, Tim Cook, said as much in an interview in early 2019, where he said healthcare is the future of the tech giant. 


"If you zoomed out into the future, and you look back, and you ask the question, 'What was Apple’s greatest contribution to mankind?' it will be about health," Tim told Mad Money's Jim Cramer. 


In 2020, the Apple boss expanded on these comments, saying tech innovations are poised to play a major role in early detection and prevention of diseases, meaning the cost of healthcare can "fundamentally be taken down, probably in a dramatic way". 


"Most of the money in healthcare goes to the cases that weren't identified early enough. It will take some time, but things that we are doing now ... those give me a lot of cause for hope."

Tim Cook, January 2020


The fact of the matter is that medicine does not work without imaging; without a way to figure out what needs to be treated, treatment is pointless. 


ASX-listed advanced human imaging tech developer MyFiziq is emerging as a market leader in this space. The company has shifted from an app development partner business to a disruptor of the medical imaging industry through the MYQ proprietary body-scanning technology. 


Crucial observations at the tip of your finger


MyFiziq's tech is more than just the latest fad in the fitness world. 


Yes, the app can certainly be used to track key measurements for a user's weight loss journey, but the technology has evolved far beyond this. MYQ's tech provides the same quality of medical observation that was previously only available from a GP or in a clinic. 

Essentially, there are two key arms of medical imaging: diagnostics and observation. These two are complementary. 


An x-ray, for example, is generally diagnostic. A clinician sees precisely which bone is fractured, which soft tissue is damaged, or which organ is torn. Often, however, imaging is a bit more complicated. 


Generally, several vital signs and health markers need to be analysed and observed before a patient can be accurately diagnosed. This includes vital signs like blood pressure, heart rate variation, pulse, and more — precisely what MyFiziq's tech is able to observe through a mobile phone. 


The tech measures the human form across 12,000 data points. From this information, several vital markers can be analysed for a range of chronic conditions, including Type 2 diabetes, cardiovascular disease, and obesity. 


Moreover, MYQ recently embedded facial scanning into its tech capabilities. The technology is so sophisticated that through a mobile phone, MYQ can perform transdermal optical imaging (TOI) — detecting subtle changes in skin colour to accurately detect blood pressure, heart rate, respiratory rate, and more. 


This, in turn, lets the tech capture a number of key vital signs that signal a user's blood pressure, cardiac load, and risk of having a stroke, along with several other conditions. 


On top of this, MyFiziq recently struck a deal with Canada-based Triage Technologies, which specialises in artificial intelligence (AI) for detecting skin disease. 


This AI tech will be distributed through the MYQ CompleteScan offering, which will expand MyFiziq's medical imaging capabilities into over 580 skin conditions and all types of skin cancers. 


With this expanded tech on the horizon, MYQ is a clear game changer for the world of medical imaging. 



As critical as it is profitable

In Australia alone, medical imaging is a $4 billion industry. According to market research from IBISWorld, the industry covers 3000 businesses across the nation and employs over 20,000 people.


On a global scale, Grand View Research pegged medical imaging at US$20.13 billion (around A$27 billion) in 2017 with a predicted compound annual growth rate for the industry of 4 per cent.


Fortune Business Insights had the medical imaging market at US$33.69 billion (roughly A$45 billion) in 2019. 

This is because of the potential the industry has to save lives across the world.


"It is important to understand that 70 per cent of deaths each year are attributable to preventable disease," MyFiziq CEO Vlado Bosanac said. 


"A large portion of these preventable conditions is due to a person being overweight or obese." 


The mortality rate for these chronic conditions — including cardiovascular disease, diabetes, and even cancer — dwindles based on how early warning signs can be detected. 


For example, research from the National Cancer Institute shows that prostate cancer has a 28 per cent five-year survival rate without early detection. With early detection, the five-year survival for prostate cancer is 100 per cent. 


Breast cancer has a 28 per cent five-year survival rate without early detection and a 99 per cent rate with. Similarly, ovarian cancer is 27 per cent without and 92 per cent with. 


This has lead to a shift in the way healthcare companies innovate; clinicians and medical professionals already know how to find issues in the body — the challenge, then, is to do this as quickly, cheaply, and efficiently as possible.


The more medical imaging evolves, the more lives it can save. 


And this has also revolutionised how savvy investors hedge their bets on healthcare. 




The importance of a trusted brand

Medicine is a conservative industry. Consumers naturally gravitate towards known brands that have established their safety and efficacy in the market rather than newcomers trying to build up their reputation. 


This has brought about a clear trend in how medical companies operate over recent years: big brands scour the market for the latest innovations, then buy them out and sell them under their own name. 


Investors who can predict these buyouts position themselves for healthy returns. 


Take the Butterfly Network and Longview Acquisition Corp merger from November 2020 as an example. 


Butterfly, also a medical imaging innovator but with a focus on ultrasound technology, was the subject of a US$1.5 billion (around A$2 billion) merger with Longview, an affiliate of multi-billion-dollar healthcare investment firm Glenview. 


Glenview is a major shareholder of established healthcare giants like Tenet Healthcare, Takeda Pharmaceutical, and Bausch Health. 

The same trend is emerging in big tech players. 


Siemens, the hundred-billion dollar multinational tech conglomerate, has a dedicated healthcare arm focussed on distributing the latest innovations in medical tech. 


In August 2020, Siemens bought U.S. radiation and oncology specialist Varian Medical Systems for a neat US$16.4 billion (roughy A$22 billion). 


This follows a string of healthcare acquisitions over recent years, including Fast Track Diagnostics (FTD) and Epocal. Siemens is paying good money for the latest medical tech which it is absorbing into its healthcare business. 


GE Healthcare, the medical arm of multinational conglomerate General Electric, is also hopping on this trend. GE recently announced the buyout of Swedish startup Prismatic Sensors. The amount to be paid for Prismatic is so far undisclosed. 


In recent years, GE has also bought out U.K. meditech startup Puridify and cellular therapy specialist Asymptote. 

Another big player is Apple, which has been quietly buying out companies that come out with revolutionary healthcare apps for the past half-decade. 


Apple bought Tueo Health, which developed an app to health parents monitor children's asthma symptoms, in 2018. 


Before that, the smartphone giant bought Gliimpse, which made an app to aggregate medical records, and Beddit, a company that makes sleep monitors to be paired with an iPhone app. 



What does this mean for MyFiziq?

MyFiziq has sophisticated intellectual property which is already shaking up the world of medical imaging. 


The company has evolved beyond a simple app developer to a disruptive healthcare stock, and the implications of its proprietary body-scanning technology are starting to be noticed. 


Since the mid-March COVID-19-induced market slump, MYQ shares have increased in value by a thousandfold — from 7 cents each in March to trading consistently around $1 each since September. 


But this is just the start. 


The potential for MyFiziq's tech to save lives and return healthy profits for investors is enormous. The technology that the company has developed will lead to long-term revenues and an increasing share price. 


However, the M&A story for MyFiziq may well prove more compelling. Nimble technologies in giant medical markets are attractive to cashed-up global buyers. 


Whether MyFiziq will deliver shareholder growth and dividends or whether it will be consolidated by a global giant is not clear. Either way, the company and its technology remain primed for success. 


Shares in MYQ are trading for 99.5 cents each at the close of market on December 8.



Read the full article on The Market Herald here.



MYQ TEAMS UP WITH TRIAGE TECHNOLOGIES

arrow-down-2 Created with Sketch.


MyFiziq (ASX:MYQ) inks agreement with Triage Technologies

Health Care, Technology

ASX:MYQ    
MyFiziq (ASX:MYQ) - CEO, Vlado Bosanac - The Market Herald

CEO, Vlado Bosanac
Source: MyFiziq



  • MyFiziq (MYQ) has signed an agreement with Triage Technologies to use its artificial intelligence (AI) tech within its CompleteScan platform
  • The technology can identify 588 skin conditions, including skin cancers, via just a smartphone and is currently available in 200 countries across the globe
  • It's also been tested and proven to be as successful, if not more successful, at identifying skin condition as a certified dermatologist
  • MYQ will hand over around US$3 million (roughly A$4.05 million) in cash payments to Triage for the technology and also take a stake in the company
  • Shares in MyFiziq were placed in a trading halt ahead of this announcement, with the stock now trading up 12.6 per cent at $1.07 each



MyFiziq (MYQ) has signed an agreement with Triage Technologies to use its artificial intelligence (AI) tech within its own CompleteScan health platform.


MYQ came out of a three-day trading halt to announce the deal before market opened today, leading to a solid bump in MYQ's share price to back over $1 each.


AI tech

The AI technology MyFiziq has signed on to use essentially works to identify 588 skin conditions, including all skin cancers, via a smartphone.


Triage said the tech was currently available in 200 countries across the globe and over the last year has been used more than 500,000 times.


It has also been tested against dermatologists and proven to be more accurate than a dermatologist at times, with a U.S. patent expected to be granted next year.


The tech itself is also in high demand as an estimated one in five Americans and two in three Australians are sadly expected to develop a skin cancer by the age of 70.


"After losing a close friend to skin cancer, I set out to create the world’s best AI engine that could identify skin conditions in a cheap and accessible manner," Triage Founder Tory Jarmain said.


"I am proud to say we have achieved this with Triage," Tory added.


MYQ deal

Under the terms of the agreement, MyFiziq has agreed to pay US$3 million (roughly A$4.05 million) in cash to Triage to access its AI tech.


The company has also agreed to issue US$3 million worth of MYQ shares to Triage, who in return will hand over a 15.19 per cent equity interest in the business to MyFiziq.


The ASX-lister doesn't expect to generate any immediate material financial return as a result of buying access to Triage's tech, with revenue instead set to come from future licencing fees.


Both companies have said they expect to integrate Triage's AI tech into the CompleteScan platform in the next quarter, with a new product to be made available then.


"I have identified Triage as a natural fit for the platform and for the expanded interest which MYQ has developed from the medical and remote care communities for triaging users, not only in the current COVID situation, but also in normal times," MYQ CEO Vlado Bosanac said.


"Triage brings a complementary offering to our CompleteScan platform, which is 'assisting in the completion of my vision in creating the 'Tricorder” of digital health screening in your hand," he added.


Shares in MyFiziq are trading 12.6 per cent in the green at $1.07 per share at 2:18 pm AEDT.



Read the full article on The Market Herald here.

MYQ SIGNS MAJOR DEAL WITH MVMNT

arrow-down-2 Created with Sketch.


MyFiziq (ASX:MYQ) signs major deal with MVMNT for fitness tech

Health Care

ASX:MYQ    

MyFiziq (ASX:MYQ) - CEO, Vlado Bosanac - The Market Herald

CEO, Vlado Bosanac
Source: MyFiziq

  • Health tech company MyFiziq (MYQ) has struck a two-year deal with fitness company MVMNT today 
  • Under the deal, MVMNT will integrate MyFiziq's body scanning tech into its core mobile technology platform
  • Importantly, the first MVMNT partners to integrate the MYQ tech include Floyd Mayweather Boxing and Fitness, McGregor Fast by Conor McGregor, and Fitocracy
  • MyFiziq will be paid subscription fees based on how many users take up the tech each month
  • Initially, MYQ is targeting over 1.15 million subscribers at US$1 (around A$1.42) per user per month for a potential US$13.9 million (roughly A$19.76 million) in annual revenue
  • Shares in the company are up 0.42 per cent and worth $1.20 each this afternoon 



Health tech company MyFiziq (MYQ) has struck a two-year deal with fitness company MVMNT today.


MVMNT is the tech delivery arm of FitLab, which itself is a fitness and sports lifestyle brand. 


Under today's deal, MVMNT will integrate the MyFiziq body scanning tech into its core mobile technology platform. MyFiziq's product will then be available to all subscribers within MVMNT's branded digital training experiences. 


MyFiziq's tech is designed to provide accurate body measurements through nothing more than a mobile phone. Using their phone's camera, a user can scan their body to track key fitness results and provide detailed and important feedback.


Now, MyFiziq is leveraging some big names in the fitness world to boost revenue and product awareness: the first MVMNT partners to integrate the MYQ tech include Floyd Mayweather Boxing and Fitness, McGregor Fast by Conor McGregor, and Fitocracy. 


As some of the most popular fighters in the United Fighting Championship (UFC), Connor McGregor and Floyd Mayweather have a combined Instagram reach of 50 million people. 


As such, MyFiziq said it is confident in the potential of its digital training offerings and the additional value that will be brought to fitness consumers by the MVMNT integration of MYQ tech. 


Where's the money?

In return for access to the MyFiziq tech, MVMNT will pay user fees, data storage fees, and support fees to MYQ. 


Under the deal, MyFiziq will be paid user subscription fees as follows: US$1.50 (roughly A$2.10) per user per month for less than one million active users, US$1 (roughly A$1.42) per user per month for between one million and three million active users, and US$0.80 (roughly A$1.15) per user per month for three million active users or more. 


With this in mind, MyFiziq is targeting 500,000 active monthly users from Fitocracy, 410,000 monthly users from Mayweather Boxing and Fitness, and 250,000 monthly users from McGregor Fast — making up initial target user numbers from the MVMNT contract of 1.16 million people. 


Based on the company's targets, there's a potential US$13.9 million (roughly A$19.76 million) in annual revenue from today's deal. 

Shares in MYQ are trading a slight 0.42 per cent higher this afternoon, currently worth $1.20 each at 1.40 pm AEDT.


Read the full article on The Market Herald Here

MYQ CAPITAL RAISE FOR NASDAQ IPO

arrow-down-2 Created with Sketch.


MyFiziq (ASX:MYQ) prepares for capital raise, gears up for NASDAQ IPO

ASX:MYQ    
MCAP $156.3M

MyFiziq (ASX:MYQ) - CEO & Co Founder, Vlado Bosanac - The Market Herald

  • MyFiziq (MYQ) shares have entered a trading halt as the healthtech stock prepares for a capital raise
  • While the details of the raise are yet to be released, MYQ shares should resume trade by Wednesday, October 15
  • Until then, shareholders won't know just how much the company intends to raise or what the funding will be used for
  • MyFiziq's latest fundraising foray comes just one week after the company signed two health monitoring deals with Nexus-Vita and Jayex Healthcare
  • Within the next fortnight, the company should also receive a final payment to support its proposed NASDAQ initial public offering 
  • MYQ shares ended the week trading for $1.36, and will remain at this price until the company's trading halt lifts later this week

MyFiziq (MYQ) shares have entered a trading halt as the healthtech stock prepares for a capital raise.


While the details of the raise are yet to be released, MYQ shares should resume trade by Wednesday, October 15.


Until then, shareholders won't know just how much the company intends to raise or what the funding will be used for.


MyFiziq's latest fundraising foray comes just one week after the company signed two health monitoring deals.


The first, inked with Singapore's Nexus-Vita, will see MyFiziq incorporate its CompleteScan technology with the company's health monitoring platform in a deal worth at least US$3.6 million (around A$5 million) in annual revenue.


Then, on Thursday, MyFiziq announced it had signed a similar agreement with the U.K.'s Jayex Healthcare (JHL). Under the agreement, MYQ will also combine its body scanning platform with Jayex's technology.


While MYQ is yet to see the financial impact of this latest deal, it does expect to generate licence and other fees in the future.


To close off the week, MyFiziq announced it had engaged Ladenburg Thalmann & Co. as lead underwriter as it gears up to list on the NASDAQ.


It comes as MYQ awaits the last funding instalment from Asia Cornerstone Asset Management (ACAM), which offered the company US$1.5 million (around A$2.08 million) to fund its float on the tech-heavy U.S. exchange.


Under that agreement, MyFiziq should receive a final US$375,000 (around A$522,385) payment within the next fortnight.


MYQ shares ended the week trading for $1.36, and will remain at this price until the company's trading halt lifts later this week.


Read the full article on The Market Herald Here

VIDEOS

arrow-down-2 Created with Sketch.

(ASX:AHI) sign deal with E.U. health services provider



Advanced Human Imaging’s (ASX:AHI) DermaScan AI given all-clear for European markets




Advanced Human Imaging (ASX:AHI) shares jump on Jana Care Deal



Advanced Human Imaging (ASX:AHI) begins testing CompleteScan pilot



Advanced Human Imaging (ASX:AHI) one step closer to Physimax buyout




AHI signs marketing agreement with Tinjoy



AHI provides vital support to Telehealth industry



MyFiziq team up with Jayex Healthcare - The Market Herald Live, October 2020



MyFiziq secures AUD$5M in annual revenue from Nexus-Vita Deal




MyFiziq and Biomorphik accelerate launch of integrated product - The Market Herald Live News - September 2020





CompleteScan identifying risk for early intervention - MyFiziq September 



MyFiziq and The Market Herald Dealroom Interview - September 2020





Investor Updates with MyFiziq - September 2020



The Market Herald Live - September





MyFiziq - The Intel Inside of Body Measurement - August 2020





The Market Herald Live - August 2020





Investor Updates with Vlado Bosanac, ED and CEO MyFiziq - July 2020





Investor Updates with Vlado Bosanac, ED and CEO MyFiziq - July 2020





Investor Updates with Vlado Bosanac, CEO MyFiziq - June 2020




(20min delay)
Last
$1.30
Change
0.045(3.59%)
Mkt cap ! $177.2M
Open High Low Value Volume
$1.24 $1.31 $1.22 $237.9K 187.9K

Buyers (Bids)

No. Vol. Price($)
2 10499 $1.26
 

Sellers (Offers)

Price($) Vol. No.
$1.30 12528 1
View Market Depth
Last trade - 16.10pm 14/06/2021 (20 minute delay) ?
(live)
Last
$1.27
  Change
0.045 ( 0.39 %)
Open High Low Volume
$1.26 $1.31 $1.26 8555
Last updated 15.56pm 14/06/2021 (live) ?
AHI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.